Table 1 Characteristics of the breast cancer patients (hosts) and the breast tumors, overall and stratified by BMI; presented as means (SD) or % (n)

From: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer

Characteristics

Total

BMI

 
 

(n = 107)a

<25 kg/m2 (n = 62)a

≥25 kg/m2 (n = 45)a

P-value

 

Mean (SD)/% (n)

Mean (SD)/%(n)

Mean (SD)/%(n)

 

Age at diagnosis, years

55.2 (8.17)

53.7 (7.8)

57.2 (8.3)

0.025

Number of children

1.59 (1.18)

1.55 (1.18)

1.64 (1.19)

0.680

Postmenopausal

70.1 (75)

62.9 (39)

80.0 (36)

0.057

Body fat measures

 BMI, kg/m2

24.9 (3.65)

22.3 (1.8)

28.3 (2.6)

<0.001

 WHR, cm

0.88 (0.06)

0.86 (0.05)

0.90 (0.05)

<0.001

 DXA, fat trunk percent

37.3 (9.47)

32.4 (8.2)

44.0 (6.6)

<0.001

Serum biomarkers

 Cholesterol, mmol/L

5.61 (0.96)

5.42 (0.91)

5.88 (0.96)

0.014

 HDL-cholesterol, mmol/L

1.88 (0.55)

1.98 (0.49)

1.74 (0.59)

0.026

 LDL-cholesterol, mmol/L

3.38 (0.91)

3.18 (0.86)

3.66 (0.90)

0.007

 Triglycerides, mmol/L

1.07 (0.53)

0.85 (0.35)

1.36 (0.60)

<0.001

 CRP, mg/Lb

0.80 (2.10)

0.00 (1.23)

1.80 (2.60)

<0.001

 Glucose, mmol/L

5.43 (0.64)

5.27 (0.61)

5.63 (0.62)

0.004

 HbA1c

5.48 (0.38)

5.43 (0.41)

5.56 (0.34)

0.103

Medications

 Hormone users, %

29.9 (32)

32.3 (20)

26.7 (12)

0.530

 Statin users, %

4.67 (5)

4.84 (3)

4.44 (2)

0.820

 NSAID users, %

41.1 (44)

40.3 (25)

42.2 (19)

0.840

Surgical treatment

 Conservative surgery, %

71.0 (76)

59.7 (37)

86.7 (39)

0.003

 Mastectomy, %

29.0 (31)

40.3 (25)

13.3 (6)

 

 Right breast, %

43.0(46)

38.7 (24)

48.9 (22)

0.111

 Bilateral, %

1.90 (2)

0

4.44 (2)

 

Breast tumor characteristics

Histology

  Invasive ductal carcinoma, %

81.1(86)

80.3 (49)

82.2 (37)

 

  Invasive lobular carcinoma, %

13.2 (14)

14.8 (9)

11.1 (5)

0.814

  Others, %

5.61 (6)

4.84 (3)

6.67 (3)

 

  Tumor diameter, mm

16.4 (9.55)

17.3 (10.7)

15.2 (7.50)

0.265

 Grade, %

  1

30.8 (33)

27.4 (17)

35.6 (16)

 

  2

47.7 (51)

48.4 (30)

46.7 (21)

0.584

  3

21.5 (23)

24.2 (15)

17.8 (8)

 

  Ki67 hotspot, %

29.4 (21.6)

30.9 (22.0)

27.2 (21.0)

0.388

  Nodal metastasis positive, %

25.2 (27)

27.4 (17)

22.2 (10)

0.654

  ER positive, %

90.7 (97)

90.3 (56)

91.1 (41)

1.000

  ER percent

84.2 (30.4)

82.9 (30.8)

86.0 (30.1)

0.607

 PgR positive, %

69.2 (74)

72.6 (45)

64.6 (29)

0.402

  PgR percent

52.4 (41.1)

53.1 (40.0)

51.4 (43.0)

0.842

  HER2 positive, %

5.61 (6)

6.45 (4)

4.44 (2)

1.000

Fat tissue surrounding tumor

  CLS density, CLS/cm2 b

0.30 (1.30)

0.00 (0.66)

1.03 (2.00)

<0.001

  Area fat tissue, cm2

2.01 (1.06)

1.85 (0.93)

2.23 (1.20)

0.076

  Adipocyte diameter, µm

64.3 (12.9)

60.4 (11.9)

69.7 (12.4)

<0.001

  Adipocyte number, n

306 (120)

341 (130)

257 (85.3)

<0.001

  1. SD standard deviation, BMI body mass index (kg/m2), WHR waist-hip ratio, HDL high-density lipoprotein, LDL, low-density lipoprotein, CRP C-reactive protein, NSAID nonsteroidal anti-inflammatory drugs, ER estrogen receptor (ER positive when ≥1%), PgR progesterone receptor (PgR positive when ≥10%), HER2 human epidermal growth factor receptor 2, CLS crown-like structure
  2. a Number of patients may vary due to missing information
  3. b Median and interquartile range
Back to article page